CD274 and glioblastoma: In the first study conducted in recurrent glioblastoma, the combination of anti-PD-L1 antibody avelumab and axitinib (a tyrosine kinase inhibitor selective for VEGF receptors) did not meet the study threshold for activity (six-mo PFS being 18%) [19].